Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Seok Joon ShinSungjin ChungSoo Jung KimEun-Mi LeeYoung-Hye YooJi-Won KimYu-Bae AhnEun-Sook KimSung-Dae MoonMyung-Jun KimSeung Hyun KoPublished in: PloS one (2016)
Dapagliflozin treatment showed beneficial effects on diabetic nephropathy, which might be via suppression of renal RAS component expression, oxidative stress and interstitial fibrosis in OLETF rats. We suggest that, in addition to control of hyperglycemia, partial suppression of renal RAS with an SGLT2 inhibitor would be a promising strategy for the prevention of treatment of diabetic nephropathy.